Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic criteria for squamous cell cancer of the skin.
Jensen V, Prasad AR, Smith A, Raju M, Wendel CS, Schmelz M, Leyva W, Warneke J, Krouse RS. Jensen V, et al. Among authors: schmelz m. J Surg Res. 2010 Mar;159(1):509-16. doi: 10.1016/j.jss.2008.12.008. Epub 2009 Jan 1. J Surg Res. 2010. PMID: 19375720
Laminin-5-mediated gene expression in human prostate carcinoma cells.
Calaluce R, Kunkel MW, Watts GS, Schmelz M, Hao J, Barrera J, Gleason-Guzman M, Isett R, Fitchmun M, Bowden GT, Cress AE, Futscher BW, Nagle RB. Calaluce R, et al. Among authors: schmelz m. Mol Carcinog. 2001 Feb;30(2):119-29. doi: 10.1002/1098-2744(200102)30:2<119::aid-mc1020>3.0.co;2-n. Mol Carcinog. 2001. PMID: 11241759
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. Puvvada SD, et al. Among authors: schmelz m. Leuk Lymphoma. 2016 Oct;57(10):2359-69. doi: 10.3109/10428194.2015.1135431. Epub 2016 Jan 12. Leuk Lymphoma. 2016. PMID: 26758422 Free PMC article. Clinical Trial.
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Kelly KR, et al. Among authors: schmelz m. Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6. Clin Cancer Res. 2018. PMID: 30082475 Free PMC article. Clinical Trial.
376 results